Pasar al contenido principal

CONTROL TRANSCRIPCIONAL DEL DESARROLLO DEL ADENOCARCINOMA DE PANCREAS

SAF2015-70553-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Deciphering the roadmap of in vivo reprogramming toward pluripotency

  • Chondronasiou, Dafni
  • Martínez de Villarreal, Jaime
  • Melendez, Elena
  • Lynch, Cian J.
  • Del Pozo, Natalia
  • Kovatcheva, Marta
  • Aguilera, Mònica
  • Prats, Neus
  • Real, Francisco X.
  • Serrano, Manuel
Differentiated cells can be converted into pluripotent stem cells by expressing the transcription factors OCT4, SOX2, KLF4, and MYC (OSKM) in a process known as reprogramming. Here, using single-cell RNA sequencing of pancreas undergoing reprogramming, we identify markers along the trajectory from acinar cell identity to pluripotency. These markers allow direct in situ visualization of cells undergoing dedifferentiation and acquiring features of early and advanced intermediate reprogramming. We also find that a fraction of cells do not dedifferentiate upon OSKM expression and are characterized by stress markers of the REG3 and AP-1 families. Importantly, most markers of intermediate reprogramming in the pancreas are also observed in stomach, colon, and cultured fibroblasts expressing OSKM. Among them is LY6A, a protein characteristic of progenitor cells and generally upregulated during tissue repair. Our roadmap defines intermediate reprogramming states that could be functionally relevant for tissue regeneration and rejuvenation., Work in the laboratory of F.X.R. was funded by grants from the Spanish Ministry of Science co-funded by the ERDF-EU (SAF2015-70553-R and RTI2018-101071-B-I00). Work in the laboratory of M.S. was funded by the IRB and by grants from the Spanish Ministry of Science co-funded by the ERDF-EU (SAF2017-82613-R), European Research Council (ERC-2014-AdG/669622), Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282), “la Caixa” Foundation, and the Milky Way Research Foundation. The CNIO and IRB are supported by the Spanish Ministry of Science as Centres of Excellence “Severo Ochoa.”
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Essential roles of cohesin STAG2 in mouse embryonic development and adult tissue homeostasis

  • De Koninck, Magali
  • Lapi, Eleonora
  • Badía Careaga, Claudio
  • Cossío, Itziar
  • Giménez-Llorente, Daniel
  • Rodríguez-Corsino, Miriam
  • Andrada, Elena
  • Hidalgo, Andrés
  • Manzanares, Miguel
  • Real, Francisco X.
  • Losada, Ana
Cohesin mediates sister chromatid cohesion and 3D genome folding. Two versions of the complex carrying STAG1 or STAG2 coexist in somatic vertebrate cells. STAG2 is commonly mutated in cancer, and germline mutations have been identified in cohesinopathy patients. To better understand the underlying pathogenic mechanisms, we report the consequences of Stag2 ablation in mice. STAG2 is largely dispensable in adults, and its tissue-wide inactivation does not lead to tumors but reduces fitness and affects both hematopoiesis and intestinal homeostasis. STAG2 is also dispensable for murine embryonic fibroblasts in vitro. In contrast, Stag2-null embryos die by mid-gestation and show global developmental delay and defective heart morphogenesis, most prominently in structures derived from secondary heart field progenitors. Both decreased proliferation and altered transcription of tissue-specific genes contribute to these defects. Our results provide compelling evidence on cell- and tissue-specific roles of different cohesin complexes and how their dysfunction contributes to disease., This work has been supported by the State Research Agency (AEI), Spanish Ministry of Science and Innovation, with cofunding of the European Regional Development Funds (grants BFU2013-48481-R and BFU2016-79841-R to A.L., SAF2015-70553-R to F.X.R., BFU2017-84914-P and BFU2015-72319-EXP to M.M., and BES-2014-069166 fellowship to M.D.K.), and a grant to F.X.R. and a Postdoctoral Contract to E.L. from the Fundación Científica de la Asociación Española Contra el Cáncer. Both CNIO and CNIC are supported by Instituto de Salud Carlos III (ISCIII) and Severo Ochoa Centers of Excellence (SEV-2015-0510 and SEV-2015-0505). The CNIC is also supported by the Pro CNIC Foundation.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer

  • Kalisz, Mark
  • Bernardo, Edgar
  • Maestro, Miguel Ángel
  • Grau, Vanessa
  • Real, Francisco X.
  • Ferrer, Jorge
Defects in transcriptional regulators of pancreatic exocrine differentiation have been implicated in pancreatic tumorigenesis, but the molecular mechanisms are poorly understood. The locus encoding the transcription factor HNF1A harbors susceptibility variants for pancreatic ductal adenocarcinoma (PDAC), while KDM6A, encoding Lysine-specific demethylase 6A, carries somatic mutations in PDAC. Here, we show that pancreas-specific Hnf1a null mutant transcriptomes phenocopy those of Kdm6a mutations, and both defects synergize with KrasG12D to cause PDAC with sarcomatoid features. We combine genetic, epigenomic, and biochemical studies to show that HNF1A recruits KDM6A to genomic binding sites in pancreatic acinar cells. This remodels the acinar enhancer landscape, activates differentiated acinar cell programs, and indirectly suppresses oncogenic and epithelial-mesenchymal transition genes. We also identify a subset of non-classical PDAC samples that exhibit the HNF1A/KDM6A-deficient molecular phenotype. These findings provide direct genetic evidence that HNF1A deficiency promotes PDAC. They also connect the tumor-suppressive role of KDM6A deficiency with a cell-specific molecular mechanism that underlies PDAC subtype definition., This research was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. Work was funded by grants from the Wellcome Trust (WT101033 to J.F.), Medical Research Council (MR/L02036X/1 to J.F.), European Research Council Advanced Grant (789055 to J.F.), Ministerio de Ciencia e Innovación (BFU2014‐54284‐R, RTI2018‐095666‐B‐I00 to J.F., SAF2011‐29530 and SAF2015‐70553‐R to F.X.R.) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034, RD12/0036/0050) to F.X.R. M.K. was supported by a Juvenile Diabetes Research Foundation postdoctoral fellowship (3‐PDF‐2014‐192‐A‐N). I.M. was supported by a Fellowship from Fundació Bancaria La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). Work in CRG was supported by the CERCA Programme, Generalitat de Catalunya, and support from Ministerio de Ciencia e Innovación to the EMBL partnership. Work at CRG and CNIO was supported by Centro de Excelencia Severo Ochoa grants SEV‐2012‐0208, SEV‐2016‐0510.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

NFIC regulates ribosomal biology and ER stress in pancreatic acinar cells and restrains PDAC initiation

  • Cobo, Isidoro
  • Paliwal, Sumit
  • Bodas, Cristina
  • Felipe, Irene
  • Melià-Alomà, Júlia
  • Torres, Ariadna
  • Martínez-Villarreal, Jaime
  • Malumbres, Marina
  • García, Fernando
  • Millán, Irene
  • Del Pozo, Natalia
  • Park, Joo-Cheol
  • MacDonald, Ray J.
  • Muñoz, Javier
  • Méndez, Raúl
  • Real, Francisco X.
Pancreatic acinar cells rely on PTF1 and other transcription factors to deploy their transcriptional program. We identify NFIC as a NR5A2 interactor and regulator of acinar differentiation. NFIC binding sites are enriched in NR5A2 ChIP-Sequencing peaks. Nfic knockout mice have a smaller, histologically normal, pancreas with reduced acinar gene expression. NFIC binds and regulates the promoters of acinar genes and those involved in RNA/protein metabolism, and Nfic knockout pancreata show defective ribosomal RNA maturation. NFIC dampens the endoplasmic reticulum stress program through binding to gene promoters and is required for resolution of Tunicamycin-mediated stress. NFIC is down-regulated during caerulein pancreatitis and is required for recovery after damage. Normal human pancreata with low levels of NFIC transcripts display reduced expression of genes down-regulated in Nfic knockout mice. NFIC expression is down-regulated in mouse and human pancreatic ductal adenocarcinoma. Consistently, Nfic knockout mice develop a higher number of mutant Kras-driven pre-neoplastic lesions., This work was supported, in part, by grants SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00 from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (co-funded by the ERDF-EU) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034) to FXR and grants PID2020-119533GB-I00, from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain), and GCB15152955MÉND, from the Spanish Association Against Cancer (AECC), to RM. I.C. was recipient of a Beca de Formación del Personal Investigador from Ministerio de Economía y Competitividad (Madrid, Spain). The research leading to these results has received funding from People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) (REA grant agreement n° 608765”). S.P. was supported by a Juan de la Cierva Programme fellowship from Ministerio de Ciencia, Innovación y Universidades. C.B. is supported by a FPI Fellowship from Ministerio de Ciencia, Innovación y Universidades. I.M. was supported by a Fellowship from Fundació Bancària La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver

  • Hruschka, Natascha
  • Andreu Martínez, David
  • Real, Francisco X.
  • Martinelli, Paola
As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have different functions and should not be lumped into one class. The transcription factor GATA3 is a paradigm of this. We investigated the functions of the most common GATA3 mutation (X308_Splice) and five additional mutations, which converge into a neoprotein that we called "neoGATA3," associated with excellent prognosis in patients. Analysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the ER-dependent transcriptional response in tumors carrying neoGATA3-generating mutations. Mechanistic studies in vitro showed that neoGATA3 interferes with the transcriptional programs controlled by estrogen and progesterone receptors, without fully abrogating them. ChIP-Seq analysis indicated that ER binding is reduced in neoGATA3-expressing cells, especially at distal regions, suggesting that neoGATA3 interferes with the fine tuning of ER-dependent gene expression. This has opposite outputs in distinct hormonal context, having pro- or anti-proliferative effects, depending on the estrogen/progesterone ratio. Our data call for functional analyses of putative cancer drivers to guide clinical application., Work in the lab of PM was supported by the Institute of Cancer Research of the Medical University Vienna and by the grant P27361-B23 from the Austrian Science Grant (FWF), FXR was supported by SAF2011-29530 and SAF2015-70553-R grants from Ministerio de Economía y Competitividad (Madrid, Spain) (co-funded by the ERDF-EU), Fundación Científica de la Asociación Española Contra el Cáncer. CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510. Work in the lab of JSC and CC was supported by Cancer Research UK. Work in the lab of SRM was supported by the Spanish Ministry of Science, Innovation and Universities (BFU2016-80570-R; AEI/FEDER, UE).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loss of GATA4 causes ectopic pancreas in the stomach

  • Rodríguez-Seguel, Elisa
  • Villamayor Coronado, Laura
  • Arroyo, Noelia
  • Andrés, Mónica P. de
  • Real, Francisco X.
  • Martín, Franz
  • Cano González, David A.
  • Rojas, Anabel
Pancreatic heterotopia is defined as pancreatic tissue outside its normal location in the body and anatomically separated from the pancreas. In this work we have analyzed the stomach glandular epithelium of Gata4 flox/flox; Pdx1‐Cre mice (Gata4KO mice). We found that Gata4KO glandular epithelium displays an atypical morphology similar to the cornified squamous epithelium and exhibits upregulation of forestomach markers. The developing gastric units fail to form properly, and the glandular epithelial cells do not express markers of gastric gland in the absence of GATA4. Of interest, the developing glands of the Gata4KO stomach express pancreatic cell markers. Furthermore, a mass of pancreatic tissue located in the subserosa of the Gata4KO stomach is observed at adult stages. Heterotopic pancreas found in Gata4‐deficient mice contains all three pancreatic cell lineages: ductal, acinar, and endocrine. Moreover, Gata4 expression is downregulated in ectopic pancreatic tissue of some human biopsy samples., ER‐S. was supported by a ‘Juan de la Cierva’ postdoctoral fellowship from the Spanish Ministry of Economy and Competitiveness (IJCI‐2014‐19251). LV was supported by a contract from Spanish Ministry of Economy and Competitiveness (RYC‐2013‐14533). This work was supported by grants from the Spanish Ministry of Economy and Competitiveness BFU2017‐82497‐P to AR, ISCIII‐Subdirección General de Evaluación y Fomento de la Investigación co‐funded with Fondos FEDER, PI16/00175 to DAC, the Andalusian Ministry of Science and Innovation CTS‐7478 to DAC, and grant SAF2015‐70553‐R to FXR. CNIO is supported by the “Ministerio de Ciencia, Innovación y Universidades” as a Centro de Excelencia Severo Ochoa (SEV‐2015‐0510)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Essential roles of cohesin STAG2 in mouse embryonic development and adult tissue homeostasis

  • De Koninck, Magali
  • Lapi, Eleonora
  • Badía Careaga, Claudio
  • Cossío, Itziar
  • Giménez-Llorente, Daniel
  • Rodríguez-Corsino, Miriam
  • Andrada, Elena
  • Hidalgo, Andrés
  • Manzanares, Miguel
  • Real, Francisco X.
  • Losada, Ana
Cohesin mediates sister chromatid cohesion and 3D genome folding. Two versions of the complex carrying STAG1 or STAG2 coexist in somatic vertebrate cells. STAG2 is commonly mutated in cancer, and germline mutations have been identified in cohesinopathy patients. To better understand the underlying pathogenic mechanisms, we report the consequences of Stag2 ablation in mice. STAG2 is largely dispensable in adults, and its tissue-wide inactivation does not lead to tumors but reduces fitness and affects both hematopoiesis and intestinal homeostasis. STAG2 is also dispensable for murine embryonic fibroblasts in vitro. In contrast, Stag2-null embryos die by mid-gestation and show global developmental delay and defective heart morphogenesis, most prominently in structures derived from secondary heart field progenitors. Both decreased proliferation and altered transcription of tissue-specific genes contribute to these defects. Our results provide compelling evidence on cell- and tissue-specific roles of different cohesin complexes and how their dysfunction contributes to disease., This work has been supported by the State Research Agency (AEI), Spanish Ministry of Science and Innovation, with cofunding of the European Regional Development Funds (grants BFU2013-48481-R and BFU2016-79841-R to A.L., SAF2015-70553-R to F.X.R., BFU2017-84914-P and BFU2015-72319-EXP to M.M., and BES-2014-069166 fellowship to M.D.K.), and a grant to F.X.R. and a Postdoctoral Contract to E.L. from the Fundación Científica de la Asociación Española Contra el Cáncer. Both CNIO and CNIC are supported by Instituto de Salud Carlos III (ISCIII) and Severo Ochoa Centers of Excellence (SEV-2015-0510 and SEV-2015-0505). The CNIC is also supported by the Pro CNIC Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver

  • Hruschka, Natascha
  • Andreu Martínez, David
  • Real, Francisco X.
  • Martinelli, Paola
As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have different functions and should not be lumped into one class. The transcription factor GATA3 is a paradigm of this. We investigated the functions of the most common GATA3 mutation (X308_Splice) and five additional mutations, which converge into a neoprotein that we called "neoGATA3," associated with excellent prognosis in patients. Analysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the ER-dependent transcriptional response in tumors carrying neoGATA3-generating mutations. Mechanistic studies in vitro showed that neoGATA3 interferes with the transcriptional programs controlled by estrogen and progesterone receptors, without fully abrogating them. ChIP-Seq analysis indicated that ER binding is reduced in neoGATA3-expressing cells, especially at distal regions, suggesting that neoGATA3 interferes with the fine tuning of ER-dependent gene expression. This has opposite outputs in distinct hormonal context, having pro- or anti-proliferative effects, depending on the estrogen/progesterone ratio. Our data call for functional analyses of putative cancer drivers to guide clinical application., Work in the lab of PM was supported by the Institute of Cancer Research of the Medical University Vienna and by the grant P27361-B23 from the Austrian Science Grant (FWF), FXR was supported by SAF2011-29530 and SAF2015-70553-R grants from Ministerio de Economía y Competitividad (Madrid, Spain) (co-funded by the ERDF-EU), Fundación Científica de la Asociación Española Contra el Cáncer. CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510. Work in the lab of JSC and CC was supported by Cancer Research UK. Work in the lab of SRM was supported by the Spanish Ministry of Science, Innovation and Universities (BFU2016-80570-R; AEI/FEDER, UE).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer

  • Kalisz, Mark
  • Bernardo, Edgar
  • Maestro, Miguel Ángel
  • Grau, Vanessa
  • Real, Francisco X.
  • Ferrer, Jorge
Defects in transcriptional regulators of pancreatic exocrine differentiation have been implicated in pancreatic tumorigenesis, but the molecular mechanisms are poorly understood. The locus encoding the transcription factor HNF1A harbors susceptibility variants for pancreatic ductal adenocarcinoma (PDAC), while KDM6A, encoding Lysine-specific demethylase 6A, carries somatic mutations in PDAC. Here, we show that pancreas-specific Hnf1a null mutant transcriptomes phenocopy those of Kdm6a mutations, and both defects synergize with KrasG12D to cause PDAC with sarcomatoid features. We combine genetic, epigenomic, and biochemical studies to show that HNF1A recruits KDM6A to genomic binding sites in pancreatic acinar cells. This remodels the acinar enhancer landscape, activates differentiated acinar cell programs, and indirectly suppresses oncogenic and epithelial-mesenchymal transition genes. We also identify a subset of non-classical PDAC samples that exhibit the HNF1A/KDM6A-deficient molecular phenotype. These findings provide direct genetic evidence that HNF1A deficiency promotes PDAC. They also connect the tumor-suppressive role of KDM6A deficiency with a cell-specific molecular mechanism that underlies PDAC subtype definition., This research was supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. Work was funded by grants from the Wellcome Trust (WT101033 to J.F.), Medical Research Council (MR/L02036X/1 to J.F.), European Research Council Advanced Grant (789055 to J.F.), Ministerio de Ciencia e Innovación (BFU2014‐54284‐R, RTI2018‐095666‐B‐I00 to J.F., SAF2011‐29530 and SAF2015‐70553‐R to F.X.R.) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034, RD12/0036/0050) to F.X.R. M.K. was supported by a Juvenile Diabetes Research Foundation postdoctoral fellowship (3‐PDF‐2014‐192‐A‐N). I.M. was supported by a Fellowship from Fundació Bancaria La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). Work in CRG was supported by the CERCA Programme, Generalitat de Catalunya, and support from Ministerio de Ciencia e Innovación to the EMBL partnership. Work at CRG and CNIO was supported by Centro de Excelencia Severo Ochoa grants SEV‐2012‐0208, SEV‐2016‐0510.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Deciphering the roadmap of in vivo reprogramming toward pluripotency

  • Chondronasiou, Dafni
  • Martínez de Villarreal, Jaime
  • Melendez, Elena
  • Lynch, Cian J.
  • Del Pozo, Natalia
  • Kovatcheva, Marta
  • Aguilera, Mònica
  • Prats, Neus
  • Real, Francisco X.
  • Serrano, Manuel
Differentiated cells can be converted into pluripotent stem cells by expressing the transcription factors OCT4, SOX2, KLF4, and MYC (OSKM) in a process known as reprogramming. Here, using single-cell RNA sequencing of pancreas undergoing reprogramming, we identify markers along the trajectory from acinar cell identity to pluripotency. These markers allow direct in situ visualization of cells undergoing dedifferentiation and acquiring features of early and advanced intermediate reprogramming. We also find that a fraction of cells do not dedifferentiate upon OSKM expression and are characterized by stress markers of the REG3 and AP-1 families. Importantly, most markers of intermediate reprogramming in the pancreas are also observed in stomach, colon, and cultured fibroblasts expressing OSKM. Among them is LY6A, a protein characteristic of progenitor cells and generally upregulated during tissue repair. Our roadmap defines intermediate reprogramming states that could be functionally relevant for tissue regeneration and rejuvenation., Work in the laboratory of F.X.R. was funded by grants from the Spanish Ministry of Science co-funded by the ERDF-EU (SAF2015-70553-R and RTI2018-101071-B-I00). Work in the laboratory of M.S. was funded by the IRB and by grants from the Spanish Ministry of Science co-funded by the ERDF-EU (SAF2017-82613-R), European Research Council (ERC-2014-AdG/669622), Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282), “la Caixa” Foundation, and the Milky Way Research Foundation. The CNIO and IRB are supported by the Spanish Ministry of Science as Centres of Excellence “Severo Ochoa.”
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

NFIC regulates ribosomal biology and ER stress in pancreatic acinar cells and restrains PDAC initiation

  • Cobo, Isidoro
  • Paliwal, Sumit
  • Bodas, Cristina
  • Felipe, Irene
  • Melià-Alomà, Júlia
  • Torres, Ariadna
  • Martínez-Villarreal, Jaime
  • Malumbres, Marina
  • García, Fernando
  • Millán, Irene
  • Del Pozo, Natalia
  • Park, Joo-Cheol
  • MacDonald, Ray J.
  • Muñoz, Javier
  • Méndez, Raúl
  • Real, Francisco X.
Pancreatic acinar cells rely on PTF1 and other transcription factors to deploy their transcriptional program. We identify NFIC as a NR5A2 interactor and regulator of acinar differentiation. NFIC binding sites are enriched in NR5A2 ChIP-Sequencing peaks. Nfic knockout mice have a smaller, histologically normal, pancreas with reduced acinar gene expression. NFIC binds and regulates the promoters of acinar genes and those involved in RNA/protein metabolism, and Nfic knockout pancreata show defective ribosomal RNA maturation. NFIC dampens the endoplasmic reticulum stress program through binding to gene promoters and is required for resolution of Tunicamycin-mediated stress. NFIC is down-regulated during caerulein pancreatitis and is required for recovery after damage. Normal human pancreata with low levels of NFIC transcripts display reduced expression of genes down-regulated in Nfic knockout mice. NFIC expression is down-regulated in mouse and human pancreatic ductal adenocarcinoma. Consistently, Nfic knockout mice develop a higher number of mutant Kras-driven pre-neoplastic lesions., This work was supported, in part, by grants SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00 from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (co-funded by the ERDF-EU) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034) to FXR and grants PID2020-119533GB-I00, from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain), and GCB15152955MÉND, from the Spanish Association Against Cancer (AECC), to RM. I.C. was recipient of a Beca de Formación del Personal Investigador from Ministerio de Economía y Competitividad (Madrid, Spain). The research leading to these results has received funding from People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) (REA grant agreement n° 608765”). S.P. was supported by a Juan de la Cierva Programme fellowship from Ministerio de Ciencia, Innovación y Universidades. C.B. is supported by a FPI Fellowship from Ministerio de Ciencia, Innovación y Universidades. I.M. was supported by a Fellowship from Fundació Bancària La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510.